- AstraZeneca Plc’s (NASDAQ:AZN) combination of Imfinzi (durvalumab) and Lynparza (olaparib), when added to platinum-based chemotherapy, showed positive results in the DUO-E Phase 3 trial in patients with newly diagnosed advanced or recurrent endometrial cancer.
- Lynparza is jointly developed with Merck & Co Inc (NYSE:MRK).
- Also Read: FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck’s Prostate Cancer Drug.
- The treatment followed by either Imfinzi plus Lynparza or Imfinzi alone as maintenance therapy showed a statistically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy.
- AstraZeneca said that overall survival data were immature, although a favorable trend was observed for the treatments.
- Endometrial cancer is the 6th most common cancer in women worldwide, with over 417,000 patients diagnosed and over 97,000 deaths in 2020.
- The safety and tolerability profile of Imfinzi plus chemotherapy and Imfinzi in combination with Lynparza was broadly consistent with that observed in prior clinical trials and the known profiles of the individual medicines.
- Price Action: AZN shares closed at $71.79 on Thursday.
‘The Dog Is Ready To Bite’: Crypto Analyst Foresees 23,000% Rally Repeat For Dogecoin Thanks To This Technical Signal
Crypto trader and analyst Tony “The Bull ” on Monday identified a technical signal in Dogecoin’s (CRYPTO: DOGE) price activity that may suggest an upcoming rally for the meme cryptocurrency.
